Real-World Effectiveness of PLD in Platinum- Sensitive Recurrent Ovarian Cancer

CompletedOBSERVATIONAL
Enrollment

432

Participants

Timeline

Start Date

May 17, 2018

Primary Completion Date

December 17, 2018

Study Completion Date

December 17, 2018

Conditions
Ovarian Carcinoma
Interventions
DRUG

pegylated liposomal doxorubicin (PLD) + carboplatin (CD)

carboplatin AUC 5 plus paclitaxel 175 mg/m2 every 3 weeks for at least 6 cycles

DRUG

carboplatin + paclitaxel (CP)

carboplatin AUC 5 plus paclitaxel 175 mg/m2 every 3 weeks for at least 6 cycles

Trial Locations (1)

138-736

Konkuk University School of Medicine, Seoul

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Seoul National University Hospital

OTHER

collaborator

National Cancer Center, Korea

OTHER_GOV

collaborator

Asan Medical Center

OTHER

collaborator

The Catholic University of Korea

OTHER

collaborator

Samsung Medical Center

OTHER

collaborator

Chung-Ang University Hosptial, Chung-Ang University College of Medicine

OTHER

collaborator

Ajou University

OTHER

collaborator

Severance Hospital

OTHER

lead

Konkuk University Medical Center

OTHER